Related Experiment Video
Updated: May 25, 2025
Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
Published on: August 7, 2018
RIPK1 in necroptosis and recent progress in related pharmaceutics
Kunhou Yao1, Zhihao Shi2, Fengya Zhao2
1Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
Abstract:
Necroptosis is a programmed form of cell death. Receptor-interacting serine/threonine protein kinase l (RIPK1) is a crucial protein kinase that regulates the necroptosis pathway. Increased expression of death receptor family ligands such as tumor necrosis factor (TNF) increases the susceptibility of cells to apoptosis and necroptosis. RIPK1, RIPK3, and mixed-lineage kinase-like domain (MLKL) proteins mediate necrosis. RIPK1-mediated necroptosis further promotes cell death and inflammation in the pathogenesis of liver injury, skin diseases, and neurodegenerative diseases. The N-terminal kinase domain of RIPK1 is significant in the induction of cell death and can be used as a vital drug target for inhibitors. In this paper, we outline the pathways of necroptosis and the role RIPK1 plays in them and suggest that targeting RIPK1 in therapy may help to inhibit multiple cell death pathways.
Insights
Necroptosis, a programmed cell death, is regulated by RIPK1 (Receptor-interacting serine/threonine protein kinase 1). Targeting RIPK1 may inhibit cell death pathways involved in diseases like liver injury and neurodegeneration.
Area of Science:
- Molecular Biology
- Cell Biology
- Immunology
Background:
- Necroptosis is a critical form of programmed cell death.
- Receptor-interacting serine/threonine protein kinase 1 (RIPK1) is a key regulator of necroptosis.
- Dysregulation of necroptosis is implicated in various diseases, including liver injury, skin diseases, and neurodegeneration.
Purpose of the Study:
- To elucidate the role of RIPK1 in necroptosis pathways.
- To explore the therapeutic potential of targeting RIPK1.
- To highlight RIPK1 as a drug target for inhibiting cell death.
Main Methods:
- Review of existing literature on necroptosis and RIPK1 signaling.
- Analysis of the molecular mechanisms underlying RIPK1-mediated necroptosis.
- Identification of RIPK1's N-terminal kinase domain as a potential drug target.
Main Results:
- RIPK1, RIPK3, and MLKL proteins are central mediators of necroptosis.
- Increased TNF signaling enhances susceptibility to apoptosis and necroptosis.
- RIPK1-driven necroptosis contributes to inflammation and pathogenesis in multiple diseases.
Conclusions:
- RIPK1 plays a pivotal role in orchestrating necroptosis.
- Targeting RIPK1 offers a promising therapeutic strategy to modulate cell death pathways.
- Inhibition of RIPK1 may provide a unified approach to treat diseases associated with necroptosis.
More Related Videos
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
05:52Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Related Concept Videos
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...